← Back to Screener
Evommune, Inc. (EVMN)
Price$26.77
Favorite Metrics
Price vs S&P 500 (4W)6.01%
Market Capitalization$970.33M
All Metrics
Book Value / Share (Quarterly)$6.83
Price vs S&P 500 (YTD)54.72%
Net Profit Margin (TTM)-606.20%
EPS (TTM)$-3.22
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$-3.22
EPS (Annual)$-2.29
ROI (Annual)-33.42%
Cash / Share (Quarterly)$4.96
Revenue Growth QoQ (YoY)85.71%
ROA (Last FY)-30.62%
EBITD / Share (TTM)$-3.32
Operating Margin (TTM)-744.36%
Cash Flow / Share (Annual)$-2.55
P/B Ratio4.72x
P/B Ratio (Quarterly)2.63x
Net Income / Employee (Annual)$-1
EPS Incl Extra (Annual)$-2.29
Current Ratio (Annual)8.57x
Quick Ratio (Quarterly)8.33x
3-Month Avg Trading Volume0.51M
Revenue / Employee (TTM)$0
P/S Ratio (Annual)74.64x
Asset Turnover (Annual)0.06x
52-Week High$33.20
EPS Excl Extra (Annual)$-2.29
Quick Ratio (Annual)8.33x
13-Week Price Return27.44%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.57x
Enterprise Value$926.8
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-529.77%
Cash / Share (Annual)$4.96
3-Month Return Std Dev169.17%
Net Income / Employee (TTM)$-2
ROE (Last FY)-33.50%
EPS Basic Excl Extra (Annual)$-2.29
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.22
P/S Ratio (TTM)60.65x
Revenue / Share (Annual)$0.43
Year-to-Date Return57.36%
5-Day Price Return-5.97%
EPS Normalized (Annual)$-2.29
Net Profit Margin (Annual)-529.77%
Month-to-Date Return17.18%
EBITD / Share (Annual)$-2.35
Operating Margin (Annual)-623.62%
EPS Basic Excl Extra (TTM)$-3.22
P/B Ratio (Annual)2.63x
Pretax Margin (TTM)-606.20%
Book Value / Share (Annual)$6.83
Price vs S&P 500 (13W)26.75%
Beta0.19x
Revenue / Share (TTM)$0.53
52-Week Low$13.88
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.30
4.36
4.36
4.33
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
EVMNEvommune, Inc. | 60.65x | — | — | — | $26.77 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Evommune Inc is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, including chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's pipeline features two lead candidates, EVO756 and EVO301, currently in clinical development.